Bivamelagon

Last updated
Bivamelagon
Bivamelagon.svg
Clinical data
Other namesLB54640; LB-54640; LR-19021; LR19021
Routes of
administration 		Oral
Drug class Melanocortin MC4 receptor agonist
Legal status
Legal status
  • Investigational
Identifiers
  • N-[(3S,5S)-1-[(3S,4R)-1-tert-butyl-4-(4-chlorophenyl)pyrrolidine-3-carbonyl]-5-(morpholine-4-carbonyl)pyrrolidin-3-yl]-2-methyl-N-(4-methylcyclohexyl)propanamide
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
Chemical and physical data
Formula C35H53ClN4O4
Molar mass 629.28 g·mol−1
3D model (JSmol)
  • CC1CCC(CC1)N([C@H]2C[C@H](N(C2)C(=O)[C@@H]3CN(C[C@H]3C4=CC=C(C=C4)Cl)C(C)(C)C)C(=O)N5CCOCC5)C(=O)C(C)C
  • InChI=1S/C35H53ClN4O4/c1-23(2)32(41)40(27-13-7-24(3)8-14-27)28-19-31(34(43)37-15-17-44-18-16-37)39(20-28)33(42)30-22-38(35(4,5)6)21-29(30)25-9-11-26(36)12-10-25/h9-12,23-24,27-31H,7-8,13-22H2,1-6H3/t24?,27?,28-,29-,30+,31-/m0/s1
  • Key:QLOCFNAGHBVTJD-JBHFHXMJSA-N

Bivamelagon (INN Tooltip International Nonproprietary Name; developmental code names LB54640, LR-19021) is a small-molecule melanocortin MC4 receptor agonist under development by LG Chem Life Sciences for the treatment of hypothalamic obesity, . [1] [2] Unlike the older drug with the same mechanism of action, setmelanotide, it can be taken orally. [3] [4] [5] As of March 2024, it is in phase 2 clinical trials. [1]

References

  1. 1 2 "Rhythm Pharmaceuticals". AdisInsight. 13 March 2024. Retrieved 25 February 2025.
  2. ↑ "Delving into the Latest Updates on Bivamelagon with Synapse". Synapse. 23 January 2025. Retrieved 25 February 2025.
  3. ↑ Aronne, Sarah R. Barenbaum, Louis J. (2023). "Antiobesity Medications on the Horizon". Handbook of Obesity - Volume 2 (5 ed.). CRC Press. pp. 394–401. doi:10.1201/9781003432807-42. ISBN   978-1-003-43280-7.{{cite book}}: CS1 maint: multiple names: authors list (link)
  4. ↑ First-in-Human Study of Safety, Pharmacodynamics of LB54640, An Oral Melanocortin-4 Receptor Agonist Mirza, Victoria, MD, MPH; Lee, Jisoo, MD; Gwak, Heemin; Yang, Yunjeong; Kim, Mina.  Obesity; Silver Spring Vol. 30, (Nov 2022): 145-146.
  5. ↑ Piper, Noah B.C.; Whitfield, Emily A.; Stewart, Gregory D.; Xu, Xiaomeng; Furness, Sebastian G.B. (August 2022). "Targeting appetite and satiety in diabetes and obesity, via G protein-coupled receptors". Biochemical Pharmacology. 202: 115115. doi:10.1016/j.bcp.2022.115115. PMID   35671790. S2CID   249452717.



This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.